You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for NS 1619
NS 1619 is a large-conductance Ca2+-activated potassium (BKCa, KCa1.1) channel activator. Induces a concentration-dependent decrease in mitochondrial membrane potential (EC50 = 3.6 μM).
Technical Data for NS 1619
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for NS 1619
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for NS 1619
The following data is based on the product molecular weight 362.23. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.76 mL||13.8 mL||27.61 mL|
|5 mM||0.55 mL||2.76 mL||5.52 mL|
|10 mM||0.28 mL||1.38 mL||2.76 mL|
|50 mM||0.06 mL||0.28 mL||0.55 mL|
References for NS 1619
References are publications that support the biological activity of the product.
Olesen et al (1994) Selective activation of Ca(2+)-dependent K+ channels by novel benzimidazolone. Eur.J.Pharmacol. 251 53 PMID: 8137869
Debska et al (2003) Large-conductance K+ channel openers NS1619 and NS004 as inhibitors of mitochondrial function in glioma cells. Biochem.Pharmacol. 65 1827 PMID: 12781334
Han et al (2008) The potassium ion channel opener NS1619 inhibits proliferation and induces apoptosis in A2780 ovarian cancer cells. Biochem.Biophys.Res.Comm. 375 205
If you know of a relevant reference for NS 1619, please let us know.
View Related Products by Product Action
Keywords: NS 1619, NS 1619 supplier, NS1619, Ca2+-activated, potassium, K+, KCa, KCa1.1, channels, activators, openers, large, conductance, BK, maxi-K, Ca2+-Activated, Potassium, Channels, 3804, Tocris Bioscience
1 Citation for NS 1619
Citations are publications that use Tocris products. Selected citations for NS 1619 include:
Khan et al (2019) BK channels regulate extracellular Tat-mediated HIV-1 LTR transactivation. Sci Rep 9 12285 PMID: 31439883
Do you know of a great paper that uses NS 1619 from Tocris? Please let us know.
Reviews for NS 1619
Average Rating: 4.5 (Based on 2 Reviews.)
Have you used NS 1619?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
The effect of NS161 as a therapeutic option for pulmonary hypertension was studied in rats. It can be seen from the test results that inhalation of a 12 µM and 100 µM NS1619 solution significantly reduces RV pressure without affecting systemic arterial pressure.
NS1619 inhalation reduces RV pressure and improves oxygen supply and its application inhibits PASMC proliferation in vitro.
I have used NS1619 as the standard BK channel opener compound to study how its effect measures up to few other drugs known to have BK channel activation properties. Concentrations of 0.1 microM, 1 microM, 10 microM and 100 microM were made. NS1619 was dissolved in sterile DMSO. Absorbance given off by HEK 293 cells when treated by both NS1619 and test compounds were measured by flame AAS.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.